New Study From IHU Méditerranée Infection, Marseille, France Shows Antibody-Dependent Enhancement Occurs in Humans in Weeks 1 and 2 Following COVID-19 Vaccine Administration

My 2020 analysis of efficacy after the first trials said 75%, not 95%. Animal studies against Wuhan mRNA spike vaccines were not enough and ADE should have been studied again with new variants.

Is the entire reason why two doses were used to gin efficacy?

This is the image of ADE in action. Patients who received a first dose (red) had an increased risk of COVID-19 following the jab compared to the unvaccinated. AND (this is VERY important) - the decrease in the second dose (green line) is an artifact of survivorship bias: patients who got COVID-19 after the first dose but before the second were dropped from the study.

From the study: “SARS-CoV-2 infection was significantly more likely to occur in the first 13 days post-vaccine injection in those who received a single dose (48.9%) than two doses (27.4%, p< 10–3).”

The study also reported that the death rate it the “fully vaccinated” (2.5%) was higher than the partially vaccinated (1.1%) and the unvaccinated (2%).

This is why we MUST DEMAND that all of the math of COVID-19 vaccine trials be re-calculated and then the data re-submitted to FDA for reconsideration, and all recommendations by ACIP and VRBPAC be re-cast with the actual and correct rates of infection in the vaccinatING (which I define as those in the trial who were on their way to trying to survive two jabs), the boosted, and the unvaccinated.

SARS-CoV-2 Vaccination and Protection Against Clinical Disease: A Retrospective Study, Bouches-du-Rhône District, Southern France, 2021